Siegel RL, Miller KD, Fuchs HE, Jemal A. Cancer statistics, 2022. CA Cancer J Clin 2022;72:7–33. https://doi.org/10.3322/caac.21708.

Article  PubMed  Google Scholar 

Villanueva A. Hepatocellular Carcinoma. N Engl J Med. 2019;380:1450–62. https://doi.org/10.1056/NEJMra1713263.

Article  CAS  PubMed  Google Scholar 

Vogel A, Meyer T, Sapisochin G, Salem R, Saborowski A. Hepatocellular carcinoma. Lancet. 2022;400:1345–62. https://doi.org/10.1016/S0140-6736(22)01200-4.

Article  CAS  PubMed  Google Scholar 

Reig M, Forner A, Rimola J, Ferrer-Fabrega J, Burrel M, Garcia-Criado A, et al. BCLC strategy for prognosis prediction and treatment recommendation: The 2022 update. J Hepatol 2022;76:681–93. https://doi.org/10.1016/j.jhep.2021.11.018.

Article  PubMed  Google Scholar 

Sangro B, Sarobe P, Hervas-Stubbs S, Melero I. Advances in immunotherapy for hepatocellular carcinoma. Nat Rev Gastroenterol Hepatol 2021;18:525–43. https://doi.org/10.1038/s41575-021-00438-0.

Article  PubMed  PubMed Central  Google Scholar 

Mei J, Li SH, Li QJ, Sun XQ, Lu LH, Lin WP, et al. Anti-PD-1 Immunotherapy Improves the Efficacy of Hepatic Artery Infusion Chemotherapy in Advanced Hepatocellular Carcinoma. J Hepatocell Carcinoma. 2021;8:167–76. https://doi.org/10.2147/JHC.S298538.

Article  PubMed  PubMed Central  Google Scholar 

Finn RS, Qin S, Ikeda M, Galle PR, Ducreux M, Kim TY, et al. Atezolizumab plus Bevacizumab in Unresectable Hepatocellular Carcinoma. N Engl J Med. 2020;382:1894–905. https://doi.org/10.1056/NEJMoa1915745.

Article  CAS  PubMed  Google Scholar 

Llovet JM, Castet F, Heikenwalder M, Maini MK, Mazzaferro V, Pinato DJ, et al. Immunotherapies for hepatocellular carcinoma. Nat Rev Clin Oncol. 2022;19:151–72. https://doi.org/10.1038/s41571-021-00573-2.

Article  CAS  PubMed  Google Scholar 

He M, Li Q, Zou R, Shen J, Fang W, Tan G, et al. Sorafenib Plus Hepatic Arterial Infusion of Oxaliplatin, Fluorouracil, and Leucovorin vs Sorafenib Alone for Hepatocellular Carcinoma With Portal Vein Invasion: A Randomized Clinical Trial. JAMA Oncol. 2019;5:953–60. https://doi.org/10.1001/jamaoncol.2019.0250.

Article  PubMed  PubMed Central  Google Scholar 

Li QJ, He MK, Chen HW, Fang WQ, Zhou YM, Xu L, et al. Hepatic Arterial Infusion of Oxaliplatin, Fluorouracil, and Leucovorin Versus Transarterial Chemoembolization for Large Hepatocellular Carcinoma: A Randomized Phase III Trial. J Clin Oncol 2022;40:150–60. https://doi.org/10.1200/JCO.21.00608.

Article  CAS  PubMed  Google Scholar 

Deng, M, Zhong, C, Li, D, Guan, R, Lee, C, Chen, H et al. Hepatic arterial infusion chemotherapy-based conversion hepatectomy in responders versus nonresponders with hepatocellular carcinoma: A multicenter cohort study. Int J Surg. 2024. https://doi.org/10.1097/JS9.0000000000002043.

Ouyang L, Shi Z, Zhao S, Wang FT, Zhou TT, Liu B, et al. Programmed cell death pathways in cancer: a review of apoptosis, autophagy and programmed necrosis. Cell Prolif. 2012;45:487–98. https://doi.org/10.1111/j.1365-2184.2012.00845.x.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Sun Y, Peng ZL. Programmed cell death and cancer. Postgrad Med J 2009;85:134–40. https://doi.org/10.1136/pgmj.2008.072629.

Article  CAS  PubMed  Google Scholar 

Shi J, Gao W, Shao F. Pyroptosis: Gasdermin-Mediated Programmed Necrotic Cell Death. Trends Biochem Sci 2017;42:245–54. https://doi.org/10.1016/j.tibs.2016.10.004.

Article  CAS  PubMed  Google Scholar 

Wang Y, Gao W, Shi X, Ding J, Liu W, He H, et al. Chemotherapy drugs induce pyroptosis through caspase-3 cleavage of a gasdermin. Nature. 2017;547:99–103. https://doi.org/10.1038/nature22393.

Article  CAS  PubMed  Google Scholar 

Zhang Z, Zhang Y, Xia S, Kong Q, Li S, Liu X, et al. Gasdermin E suppresses tumour growth by activating anti-tumour immunity. Nature. 2020;579:415–20. https://doi.org/10.1038/s41586-020-2071-9.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Hage C, Hoves S, Strauss L, Bissinger S, Prinz YTPS, et al. Sorafenib Induces Pyroptosis in Macrophages and Triggers Natural Killer Cell-Mediated Cytotoxicity Against Hepatocellular Carcinoma. Hepatology. 2019;70:1280–97. https://doi.org/10.1002/hep.30666.

Article  CAS  PubMed  Google Scholar 

Wang S, Zhang MJ, Wu ZZ, Zhu SW, Wan SC, Zhang BX, et al. GSDME Is Related to Prognosis and Response to Chemotherapy in Oral Cancer. J Dent Res. 2022;101:848–58. https://doi.org/10.1177/00220345211073072.

Article  CAS  PubMed  Google Scholar 

Yan H, Luo B, Wu X, Guan F, Yu X, Zhao L, et al. Cisplatin Induces Pyroptosis via Activation of MEG3/NLRP3/caspase-1/GSDMD Pathway in Triple-Negative Breast Cancer. Int J Biol Sci. 2021;17:2606–21. https://doi.org/10.7150/ijbs.60292.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Li RY, Zheng ZY, Li ZM, Heng JH, Zheng YQ, Deng DX, et al. Cisplatin-induced pyroptosis is mediated via the CAPN1/CAPN2-BAK/BAX-caspase-9-caspase-3-GSDME axis in esophageal cancer. Chem Biol Interact. 2022;361:109967 https://doi.org/10.1016/j.cbi.2022.109967.

Article  CAS  PubMed  Google Scholar 

Zhang CC, Li CG, Wang YF, Xu LH, He XH, Zeng QZ, et al. Chemotherapeutic paclitaxel and cisplatin differentially induce pyroptosis in A549 lung cancer cells via caspase-3/GSDME activation. Apoptosis. 2019;24:312–25. https://doi.org/10.1007/s10495-019-01515-1.

Article  CAS  PubMed  Google Scholar 

Riddell IA. Cisplatin and Oxaliplatin: Our Current Understanding of Their Actions. Met Ions Life Sci. 2018;18. https://doi.org/10.1515/9783110470734-007.

Sharif S, O’Connell MJ, Yothers G, Lopa S, Wolmark N. FOLFOX and FLOX regimens for the adjuvant treatment of resected stage II and III colon cancer. Cancer Invest. 2008;26:956–63. https://doi.org/10.1080/07357900802132550.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Livak KJ, Schmittgen TD. Analysis of relative gene expression data using real-time quantitative PCR and the 2(-Delta Delta C(T)) Method. Methods. 2001;25:402–8. https://doi.org/10.1006/meth.2001.1262.

Article  CAS  PubMed  Google Scholar 

Llovet JM, Kelley RK, Villanueva A, Singal AG, Pikarsky E, Roayaie S, et al. Hepatocellular carcinoma. Nat Rev Dis Prim. 2021;7:6 https://doi.org/10.1038/s41572-020-00240-3.

Article  PubMed  Google Scholar 

Deng, M, Lei, Q, Wang, J, Lee, C, Guan, R, Li, S et al. Nomograms for predicting the recurrence probability and recurrence-free survival in patients with hepatocellular carcinoma after conversion hepatectomy based on hepatic arterial infusion chemotherapy: a multicenter, retrospective study. Int J Surg. 2023. https://doi.org/10.1097/JS9.0000000000000376.

Li, SH, Mei, J, Cheng, Y, Li, Q, Wang, QX, Fang, CK et al. Postoperative Adjuvant Hepatic Arterial Infusion Chemotherapy With FOLFOX in Hepatocellular Carcinoma With Microvascular Invasion: A Multicenter, Phase III, Randomized Study. J Clin Oncol. 2022; JCO2201142. https://doi.org/10.1200/JCO.22.01142.

Yu P, Zhang X, Liu N, Tang L, Peng C, Chen X. Pyroptosis: mechanisms and diseases. Signal Transduct Target Ther. 2021;6:128 https://doi.org/10.1038/s41392-021-00507-5.

Article  PubMed  PubMed Central  Google Scholar 

Yu J, Li S, Qi J, Chen Z, Wu Y, Guo J, et al. Cleavage of GSDME by caspase-3 determines lobaplatin-induced pyroptosis in colon cancer cells. Cell Death Dis. 2019;10:193 https://doi.org/10.1038/s41419-019-1441-4.

Article  PubMed  PubMed Central  Google Scholar 

Zhang X, Zhang H. Chemotherapy drugs induce pyroptosis through caspase-3-dependent cleavage of GSDME. Sci China Life Sci 2018;61:739–40. https://doi.org/10.1007/s11427-017-9158-x.

Article  CAS  PubMed  Google Scholar 

Kovacs SB, Miao EA. Gasdermins: Effectors of Pyroptosis. Trends Cell Biol. 2017;27:673–84. https://doi.org/10.1016/j.tcb.2017.05.005.

Article  CAS